Table 2.

Primary and secondary endpoints

	Natriuresis-guided therapy	SOC		P value
Dual primary endpoint			Estimated between-group difference (95% CI) or HR [95% CI] if applicable
24 h natriuresis (mmol)a	409 ± 178	345 ± 202	63 (18–109)	0.0061
180 day HF rehospitalization or all-cause mortality (% (n))b	31 (46)	31 (50)	0.92 [0.62–1.38]	0.6980
Secondary endpoints (hierarchical testing)
48 h natriuresis (mmol)	653 ± 249	575 ± 290	78 (10–145)	0.0241
24 h diuresis (ml)	3,900 [3,200–4,945]	3,330 (2,510–4,500)	534 (160–908)	0.0053
48 h diuresis (ml)	6,655 (5,401–7,824)	5,915 (4,600–7,400)	672 (137–1,206)	0.0140
Length of hospital stay (days)	6 [5–9]	7 [5–10]		0.1436
HF rehospitalization (% (n))	17 (25)	17 (26)	0.96 [0.56–1.67]	0.8904
Total number of HF rehospitalizations per patient	1 [1–1]	1 [1–1]		0.7663
180 day all-cause mortality (% (n))	19 (29)	21 (33)	0.89 [0.54–1.46]	0.6369
Percentage change in NT-proBNP (%)
At 48 h	−22 [−48–12]	−18 [−41–17]		0.4351
At 72 h	−33 [−61–0]	−33 [−58–8]		0.7881

^aThe first part of the dual primary endpoint, 24 h total natriuresis, could not be assessed in 32 patients who underwent randomization (2 patients died within 24 h after admission, and 30 patients had missing urine collections). Student’s t-test.

^bThe second part of the dual primary endpoint, all-cause mortality or HF rehospitalization, could not be assessed in one patient who underwent randomization (lost to follow-up). Cox regression.

Normally distributed variables are tested with Student’s t-test, non-normally distributed values with Wilcoxon rank/sum test and categorical values with chi-square test.